US HB1375 | 2023-2024 | 118th Congress
Status
Spectrum: Moderate Partisan Bill (Democrat 5-1)
Status: Introduced on March 3 2023 - 25% progression
Action: 2023-03-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 3 2023 - 25% progression
Action: 2023-03-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.
Title
EFFECTIVE Act Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act
Sponsors
| Rep. David Trone [D-MD] | Rep. Dan Meuser [R-PA] | Rep. Ann Kuster [D-NH] | Rep. Daniel Kildee [D-MI] |
| Rep. Josh Harder [D-CA] | Rep. Brittany Pettersen [D-CO] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-03-10 | House | Referred to the Subcommittee on Health. |
| 2023-03-03 | House | Referred to the House Committee on Energy and Commerce. |
| 2023-03-03 | House | Introduced in House |
Same As/Similar To
SB607 (Same As) 2023-03-01 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/house-bill/1375/all-info |
| Text | https://www.congress.gov/118/bills/hr1375/BILLS-118hr1375ih.pdf |
